Ankaferd Blood Stopper

Oral Mucositis

Uludag UniversityN/ADormant

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 95/ 100

Competitive context

8 Active assets in the Oral Mucositis cohort.

Asset / Sponsor	Phase	Rating
Datopotamab Deruxtecan AstraZeneca	Phase 4	BB
Methylene Blue Mayo Clinic	Phase 3	BB
DEXAMETHASONE AstraZeneca	Phase 4	BB
Palifermin Swedish Orphan Biovitrum	Phase 3	B
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE US Oncology Research	Phase 2	B

View all 17 →

Same molecule, other indications

Ankaferd Blood Stopper is also rated in:

cirrhosis of liverDormant

C

Indicative ·

39 / 100

Nurse's RoleDormant

D

Indicative ·

30 / 100

chemotherapy-induced toxicityDormant

D

Indicative ·

30 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.